Trans-Subclavian Access in Transcatheter Aortic Valve Implantation: An Elegant Alternative for Non-Appropriate Transfemoral Candidates  by Ribeiro, Henrique Barbosa & Rodés-Cabau, Josep
Ribeiro & Rodés-Cabau
Trans-Subclavian Access in Transcatheter Aortic Valve Implantation
Rev Bras Cardiol Invasiva. 
2012;20(3)
1
Trans-Subclavian Access in Transcatheter Aortic  
Valve Implantation: An Elegant Alternative for  
Non-Appropriate Transfemoral Candidates
Henrique Barbosa Ribeiro1, Josep Rodés-Cabau2
Editorial
Rev Bras C rdiol Invasiva. 
2012;20(3)
1 Fellowship in Interventional and Structural Cardiology. Quebec Heart 
& Lung Institute, Laval University. Quebec city, Quebec, Canada.
2 Associate professor. Faculty of Medicine, Laval University. Director 
of the Catheterization and Interventional Laboratories, Quebec Heart 
and Lung Institute. Quebec City, Quebec, Canada.
Correspondence: Josep Rodés-Cabau. Quebec Heart & Lung Institute, 
Laval University – 2725 Chemin Ste-Foy, G1V 4G5 – Quebec City, 
Quebec, Canada
E-mail: josep.rodes@criucpq.ulaval.ca
Received on: 9/1/2012 • Accepted on: 9/2/2012
Transcatheter aortic valve implantation (TAVI) has emerged as an alternative treatment for those patients with severe aortic stenosis considered to 
be at high or prohibitive surgical risk.1 While transfe-
moral approach has been considered as the primary 
approach in the vast majority of centers and studies, 
non-optimal iliofemoral vessel characteristics preclude 
the safe placement of the sheaths in a high number 
of patients. In addition to the small size of iliofemoral 
arteries, about one third of the TAVI candidates present 
significant peripheral vascular disease.1
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Accordingly, other alternative approaches such as 
transa pical, subclavian/axillary, and transaortic have 
been developed in the recent years. The transapical 
approach has been the most frequent alternative to the 
transfemoral approach when using the balloon-ex pan -
da ble Edwards SAPIEN valve (Edwards Lifesciences, 
Irvine, USA) (> 50% of cases in the SOURCE registry; 
Table 1). More recently, and even with the use of lower 
profile sheaths, transapical TAVI is still performed in 
more than 30% of the patients.4,7,10,11 Ho wever, the tran-
sapical approach is not an option for patients receiving 
the CoreValve® system (Medtronic, Inc., Minneapolis, 
USA), so that other approaches such as the subclavian/
axil lary and the transaortic approaches have also been 
de veloped. As highlighted in Table 1, more than 90% 
of the procedures with the CoreValve® system have 
been performed transfemorally and around 5-8% were 
performed through the subclavian/axillary approach.
In this issue of the Revista Brasileira de Cardiologia 
Invasiva, Brito Júnior et al.12 reported the subclavian 
experience from the Brazilian Registry of TAVI. Among 
277 patients included in this registry, 8 patients (2.9%) 
were treated by subclavian approach with the Core-
Valve® system, all of them performed under general 
anesthesia and dissection. Even though being a small 
series, it was shown that device success was achieved 
in all cases, and there was only one major access site 
complication, also related to one death, and no ce -
re bral event at 30-day follow-up. Interestingly, the se 
results are comparable with other CoreValve® sub clavian 
registries (Table 2).
Apart from registries and small series, there is no 
randomized data to date comparing transfemoral or 
transapical approach with the subclavian approach. 
However a recent propensity-matched analysis compa -
red the procedural and 2-year results of the subclavian 
(n = 141) with those of the femoral approach (n = 141).13 
This study included all consecutive patients undergoing 
TAVI by the subclavian approach with the 18 F Co-
reValve® prosthesis, and these patients were matched 
on the basis of baseline clinical characteristics (except 
peripheral vascular disease) with a transfemoral cohort. 
Both groups showed similar procedural success rates 
(97.9% for subclavian vs. 96.5% for transfemoral; 
P = 0.47), major vascular complications (5% vs. 7.8%, 
respectively; P = 0.33), life-threatening bleeding events 
(7.8% vs. 5.7%, respectively; P = 0.48), and combi -
ned safety endpoints (19.9% vs. 25.5%, respectively; 
P = 0.26). Nonetheless, the subclavian group had lower 
rates of acute kidney injury/stage 3 (4.3% vs. 9.9%, res-
pectively; P = 0.02), minor vascular complications (2.1% 
vs. 11.3%, respectively; P = 0.003), and of all types of 
bleeding events related to vascular complications. Survi val 
at 2 years was similar in both groups (74 + 4% vs. 73.7 
+ 3.9%, respectively; P = 0.78). It should be highlighted 
that the subclavian approach was related to longer pro -
cedure times, though with similar fluoroscopy times.
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TABLE 1 
Rates of different approaches in transcatheter aortic valve implantation registries
Study n
Valve 
n (%)
Transapical
n (%)
Transfemoral
n (%)
Trans-subclavian/
axillary
n (%)
Transaortic
n (%)
Australian2 428 CoreValve® - 404 (94.4) 24 (5.6) -
Belgian3 328 CoreValve®
141 (43)
SAPIEN®
187 (57)
CoreValve®
(0) 
SAPIEN®
88 (47)
CoreValve®
133 (94) 
SAPIEN®
99 (53)
CoreValve®
8 (6)
-
Canadian4 345 Cribier,
SAPIEN®, SAPIEN XT®
177 (51.3) 168 (48.7) - -
FRANCE 25 3,195 SAPIEN®
2,137 (66.9)
CoreValve®
1,058 (33.1)
567 (17.7) 2,361 (73.9) 184 (5.8) 83 (2.6)
German6 697 SAPIEN®
109 (15.6)
CoreValve®
588 (84.4)
26 (3.7) 644 (92.4) 22 (3.2) 5 (0.7)
SOURCE7 1,038 SAPIEN® 575 (55.4) 463 (44.6) - -
SOURCE XT8 2,600 SAPIEN XT® 871 (33.5) 1,628 (62.6) 7 (0.3) 94 (3.6)
Meta-analysis9 4,871 CoreValve®
1,649 (33.9)
SAPIEN® and SAPIEN XT®
3,222 (64.1)
CoreValve®
(0)
SAPIEN®
1,840 (57.1)
CoreValve®
1,510 (91.6)
SAPIEN®
1,382 (42.9)
CoreValve®
133 (8.1)
SAPIEN®
(0)
CoreValve®
6 (0.3)
SAPIEN®
(0)
TABLE 2 
Main results of the subclavian approach cohort from transcatheter aortic valve implantation registries
Study n
Number
of centers Follow-up
Age,
years
Logistic  
EuroSCoRE, %
Procedural 
success, %
Vascular
complications, %
30-day
survival, %
FRANCE 25 184 33 1 year 82.2 20.3 96.7 10.8* 89.9
Italian13 141 10 2 years 83 23.7 97.9 12.1* 94.3
UK14 35 8 30 days 80.6 25 100 2.9† -
Netherlands15 22 1 30 days - - 95 9† 95
French16 17 4 30 days 71 34 100 0 88.2
Brazilian12 8 4 9 months 84 32 100 12.5* 87.5
* Major and minor vascular complications; † Major vascular complications.
Overall, these data including registries, small series 
and propensity-matched analysis suggest that the sub-
clavian approach is an interesting alternative to the 
trans femoral route for TAVI, and should be considered, 
especially in patients where clinical situations such 
as severe calcification, severe tortuosity, small vessels 
size diameter, preclude the femoral approach. Another 
important aspect about the subclavian access is that 
a careful analysis of the subclavian anatomy has to 
be performed, seeking for minimal diameter > 6 mm, 
avoidance of circumferential calcifications and severe 
tortuosity, and also the presence of previous ipsilateral 
pacemaker. Lastly, while the presence of previous 
coronary artery bypass graft (CABG), including the left 
internal mammary artery (LIMA), that has usually been 
considered a formal contraindication, Modine et al.17 
recently showed the feasibility and safety of the sub-
clavian approach even in 19 patients with prior CABG 
and a patent LIMA. However, a minimal subclavian 
diameter of 7 mm and sheath removal during valve 
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placement is recommended in these cases to avoid the 
occurrence of myocardial ischemia. 
In conclusion, the transfemoral approach is not pos-
sible in a high proportion of TAVI candidates. Several 
prior studies and the work from Brito Junior et al.12 in 
this issue showed that the subclavian approach using 
the CoreValve® system is a good alternative for those 
TAVI candidates with non-appropriate iliofemoral arte-
ries. Future randomized studies are needed to evaluate 
the potential superiority of this approach compared to 
other alternative approaches as well as to the trans-
femoral access.
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